{"id":"NCT00738530","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy","officialTitle":"A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-06","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2008-08-20","resultsPosted":"2016-06-23","lastUpdate":"2016-06-23"},"enrollment":649,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Renal Cell Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab [Avastin]","otherNames":[]},{"type":"DRUG","name":"Interferon alfa 2a [Roferon]","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Bevacizumab + IFN-Alfa-2A","type":"EXPERIMENTAL"},{"label":"Placebo + IFN-Alfa-2A","type":"PLACEBO_COMPARATOR"}],"summary":"This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy. The anticipated time of study treatment is 1-2 years, and the target sample size is greater than (\\>)500 individuals.","primaryOutcome":{"measure":"Percentage of Participants Who Died","timeFrame":"Baseline up to 4.25 years","effectByArm":[{"arm":"Bevacizumab + IFN-Alfa-2A","deltaMin":67.3,"sd":null},{"arm":"Placebo + IFN-Alfa-2A","deltaMin":69.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":104,"countries":["Australia","Belgium","Czechia","Finland","France","Germany","Hungary","Israel","Italy","Netherlands","Norway","Poland","Russia","Singapore","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["37146227"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":103,"n":337},"commonTop":["Pyrexia","Anorexia","Asthenia","Fatigue","Nausea"]}}